Applied Molecular Transport to Present at Evercore ISI 3rd Annual HealthCONx Conference

Rhea-AI Summary

Applied Molecular Transport Inc. (Nasdaq: AMTI) announced that CEO and co-founder, Tahir Mahmood, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 3:30 p.m. ET. This event will be accessible via a live webcast on their website, with an archived replay available for 30 days afterward.

Applied Molecular Transport is a clinical-stage biopharmaceutical company focused on developing novel oral biologic therapies for autoimmune and inflammatory diseases using its proprietary technology platform.

News Market Reaction – AMTI

-1.97%

1 alert

-1.97% News Effect

On the day this news was published, AMTI declined 1.97%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 3:30 p.m. ET.

A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly tablet and capsule forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.

AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.

Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com

Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

What event is AMTI CEO Tahir Mahmood participating in on December 1, 2020?

Tahir Mahmood will participate in the Evercore ISI 3rd Annual HealthCONx Conference.

What time does Tahir Mahmood's fireside chat start?

The fireside chat begins at 3:30 p.m. ET.

How can I access the webcast for the AMTI conference event?

The live webcast can be accessed via the Events page on the Applied Molecular Transport website.

Will there be a replay available of the AMTI conference event?

Yes, an archived replay will be available for 30 days following the event.

What is the focus of Applied Molecular Transport Inc.?

AMT focuses on developing novel oral biologic therapies for autoimmune, inflammatory, and metabolic diseases.